Target Name: SNX2
NCBI ID: G6643
Review Report on SNX2 Target / Biomarker Content of Review Report on SNX2 Target / Biomarker
SNX2
Other Name(s): sorting nexin 2 | SNX2_HUMAN | Transformation-related gene 9 protein | Sorting nexin-2 (isoform 1) | Sorting nexin 2, transcript variant 1 | SNX2 variant 1 | transformation-related gene 9 protein | CTB-36H16.2 | Sorting nexin 2 | TRG-9 | MGC5204 | Sorting nexin-2

SNX2: A Potential Drug Target and Biomarker for Ovarian Cancer

Introduction

Ovarian cancer is a leading cause of cancer death in women, with estimates suggesting that in the United States alone, over 21,000 women will be diagnosed with ovarian cancer this year. Despite advances in surgical and radiation treatments, the survival rate for ovarian cancer has remained relatively stagnant in recent years. Therefore, there is a strong need for new treatments and drug targets to improve outcomes for this disease.

SNX2, a protein that is expressed in various tissues and cell types, including the uterus, breast tissue, and the brain, has been identified as a potential drug target and biomarker for ovarian cancer. In this article, we will explore the biology of SNX2 and its potential as a drug target and biomarker for ovarian cancer.

The biology of SNX2

SNX2 is a member of the neurotrophic signaling pathway (NTS), a family of transmembrane proteins that play a critical role in the regulation of neural growth and survival. The NTS pathway has been implicated in various neurological and cancer-related diseases, including ovarian cancer.

SNX2 was first identified as a gene that was expressed in various tissues and cell types, including the uterus, breast tissue, and the brain. It is characterized by a long N-terminus that contains a unique domain that is similar to the N-terminus of the neurotrophic factors, such as N-methyl-D-aspartate (NMDA) and its receptor, N-methyl-D-aspartate (NMDA) receptor. The unique domain of SNX2 contains a putative transmembrane region and a cytoplasmic tail.

SNX2 has been shown to play a role in various physiological processes, including cell survival, proliferation, and migration. For example, studies have shown that SNX2 can promote the growth and survival of various cancer cell types, including ovarian cancer cells. Additionally, SNX2 has been shown to participate in the regulation of various cellular processes, including cell migration, invasion, and angiogenesis.

Mutational SNX2

Mutations in SNX2 have been implicated in the development and progression of various cancers, including ovarian cancer.

The impact of SNX2 mutations on cancer progression has been studied extensively. Studies have shown that SNX2 mutations can alter the expression and activity of SNX2, leading to changes in cellular processes that promote cancer cell growth and survival. For example, one study found that SNX2 Mutations can lead to increased cell motility and a decreased inhibition of cell adhesion, which can contribute to the development of invasive ovarian cancer.

In addition, SNX2 mutations have also been shown to affect the response to various chemotherapy drugs, including taxanes and anti-angiogenic drugs. This may have implications for the development of more targeted therapies for ovarian cancer.

SNX2 as a drug target

SNX2 has been identified as a potential drug target for ovarian cancer due to its involvement in various cellular processes that promote cancer cell growth and survival. Several studies have shown that inhibiting the activity of SNX2 can lead to a reduction in the growth and survival of ovarian cancer cells.

One approach to inhibiting the activity of SNX2 is through the use of small molecules that can bind to the SNX2 protein. Several studies have shown that inhibitors of SNX2, such as 1-[(3-isothiocyanatopyrrolidin-1-yl)-4

Protein Name: Sorting Nexin 2

Functions: Involved in several stages of intracellular trafficking. Interacts with membranes containing phosphatidylinositol 3-phosphate (PtdIns(3P)) or phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2) (PubMed:16179610). Acts in part as component of the retromer membrane-deforming SNX-BAR subcomplex (PubMed:17101778). The SNX-BAR retromer mediates retrograde transport of cargo proteins from endosomes to the trans-Golgi network (TGN) and is involved in endosome-to-plasma membrane transport for cargo protein recycling. The SNX-BAR subcomplex functions to deform the donor membrane into a tubular profile called endosome-to-TGN transport carrier (ETC) (Probable). Can sense membrane curvature and has in vitro vesicle-to-membrane remodeling activity (PubMed:23085988). Required for retrograde endosome-to-TGN transport of TGN38 (PubMed:20138391). Promotes KALRN- and RHOG-dependent but retromer-independent membrane remodeling such as lamellipodium formation; the function is dependent on GEF activity of KALRN (PubMed:20604901)

The "SNX2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNX2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

SNX20 | SNX21 | SNX22 | SNX24 | SNX25 | SNX27 | SNX29 | SNX29P1 | SNX29P2 | SNX3 | SNX30 | SNX31 | SNX32 | SNX33 | SNX4 | SNX5 | SNX6 | SNX7 | SNX8 | SNX9 | SOAT1 | SOAT2 | SOBP | SOCAR | SOCS1 | SOCS2 | SOCS2-AS1 | SOCS3 | SOCS3-DT | SOCS4 | SOCS5 | SOCS5P5 | SOCS6 | SOCS7 | SOD1 | SOD2 | SOD2-OT1 | SOD3 | Sodium channel | Sodium-Glucose Cotransporter (SGLT) | Sodium-potassium-calcium exchanger | SOGA1 | SOGA3 | SOHLH1 | SOHLH2 | Soluble (cytosolic) protein tyrosine phosphatases | Soluble guanylyl cyclase | Solute Carrier Family 12 | Solute carrier family 29 member | Somatostatin receptor | SON | SORBS1 | SORBS2 | SORBS3 | SORCS1 | SORCS2 | SORCS3 | SORCS3-AS1 | SORD | SORD2P | SORL1 | SORT1 | Sorting and assembly machinery complex | Sorting nexin | SOS1 | SOS2 | SOSS complex | SOST | SOSTDC1 | SOWAHA | SOWAHB | SOWAHC | SOWAHD | SOX1 | SOX1-OT | SOX10 | SOX11 | SOX12 | SOX13 | SOX14 | SOX15 | SOX17 | SOX18 | SOX2 | SOX2-OT | SOX21 | SOX21-AS1 | SOX3 | SOX30 | SOX30P1 | SOX4 | SOX5 | SOX5-AS1 | SOX6 | SOX7 | SOX8 | SOX9 | SOX9-AS1 | SP1 | SP100